Angiodynamics reports fiscal 2023 first quarter financial results; reaffirms guidance
Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the first quarter of fiscal year 2023, which ended august 31, 2022. “we are pleased with our performance during the quarter as we continued to deliver on our long-term strategic objectives,” commented jim clemmer, president and chief executive officer of angiodynamics, inc. “the challenging and uncertain macro environment continued during our first fiscal quarter of 2023, with persistent inflation, as well as hospital staffing and procedural pressures. our commitment to executing our strategic plan based on our key growth drivers: auryon, angiovac, alphavac and nanoknife, enabled us to build on the momentum we generated in fiscal 2022 to deliver solid results even in the face of this challenging environment.” first quarter 2023 financial results net sales for the first quarter of fiscal 2023 were $81.5 million, an increase of 5.9% compared to the prior-year quarter. foreign currency translation did not have a significant impact on the company's net sales in the quarter. med tech net sales were $22.8 million, a 29.6% increase from the prior-year period. med tech includes the auryon peripheral atherectomy platform, the thrombus management platform and the nanoknife irreversible electroporation platform. growth was driven by auryon sales during the quarter of $8.8 million, which increased 50.0%, thrombectomy sales of $10.0 million, which increased 31.8% and nanoknife disposable sales, which increased 12.3% compared to the first quarter of fiscal 2022. med device net sales were $58.7 million, a decline of 1.1% compared to the prior-year period. u.s. net sales in the first quarter of fiscal 2023 were $69.0 million, an increase of 7.1% from $64.5 million a year ago. international net sales were $12.5 million roughly flat compared to a year ago. gross margin for the first quarter of fiscal 2023 was 51.9%, a decrease of 20 basis points compared to the first quarter of fiscal 2022. gross margin for the med tech business was 63.2%, a decline of 220 basis points from the first quarter of fiscal 2022. gross margin for the med device business was 47.5%, a decline of 70 basis points compared to the first quarter of fiscal 2022. gross margin was negatively impacted by macro forces including labor shortages and increased costs for labor, raw materials and freight. the company recorded a net loss of $13.0 million, or a loss per share of $0.33, in the first quarter of fiscal 2023. this compares to a net loss of $7.0 million, or a loss per share of $0.18, a year ago. excluding the items shown in the non-gaap reconciliation table below, adjusted net loss for the first quarter of fiscal 2023 was $2.5 million, and adjusted loss per share was $0.06, compared to adjusted net loss of $0.9 million and adjusted loss per share of $0.02 in the prior-year period. adjusted ebitda in the first quarter of fiscal 2023, excluding the items shown in the reconciliation table below, was $3.0 million, compared to adjusted ebitda of $3.6 million in the first quarter of fiscal 2022. in the first quarter of fiscal 2023, the company used $24.7 million in operating cash, had capital expenditures of $0.8 million and additions to auryon placement and evaluation units of $2.2 million. on august 31, 2022, the company had $24.6 million in cash and cash equivalents, compared to $28.8 million in cash and cash equivalents on may 31, 2022. during the first quarter, the company refinanced its credit facility. the new credit facility provides for a $75 million secured revolving credit facility with a maturity date of august 30, 2027 and a $30 million delayed-draw term loan. the proceeds of the delayed-draw term loan may be used for general corporate purposes, including primarily to finance the manufacturing costs of the auryon laser capital equipment of angiodynamics and its subsidiaries. the company had $25.0 million outstanding on the delayed-draw term loan and $25.0 million outstanding under its revolving credit facility at august 31, 2022. fiscal year 2023 financial guidance management is reaffirming its previously issued fiscal year 2023 guidance. management expects net sales to be in the range of $342 to $348 million, gross margin to be approximately 52.5% to 54.5% and adjusted earnings per share in the range of $0.01 to $0.06 as it continues to invest in new product launches to drive future growth. conference call the company's management will host a conference call today at 8:00 a.m. et to discuss its first quarter results. to participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13732702. this conference call will also be webcast and can be accessed from the “investors” section of the angiodynamics website at www.angiodynamics.com. the webcast replay of the call will be available at the same site approximately one hour after the end of the call. a recording of the call will also be available from 11:00 a.m. et on thursday, october 6, 2022, until 11:59 p.m. et on thursday, october 13, 2022. to listen to this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13732702. use of non-gaap measures management uses non-gaap measures to establish operational goals and believes that non-gaap measures may assist investors in analyzing the underlying trends in angiodynamics' business over time. investors should consider these non-gaap measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with gaap. in this news release, angiodynamics has reported adjusted ebitda, adjusted net income and adjusted earnings per share. management uses these measures in its internal analysis and review of operational performance. management believes that these measures provide investors with useful information in comparing angiodynamics' performance over different periods. by using these non-gaap measures, management believes that investors get a better picture of the performance of angiodynamics' underlying business. management encourages investors to review angiodynamics' financial results prepared in accordance with gaap to understand angiodynamics' performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on angiodynamics' financial results. please see the tables that follow for a reconciliation of non-gaap measures to measures prepared in accordance with gaap. about angiodynamics, inc. angiodynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients. the company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. for more information, visit www.angiodynamics.com. safe harbor this release contains forward-looking statements within the meaning of the private securities litigation reform act of 1995. all statements regarding angiodynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," “projects”, "optimistic," or variations of such words and similar expressions, are forward-looking statements. these forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. investors are cautioned that actual events or results may differ materially from angiodynamics' expectations, expressed or implied. factors that may affect the actual results achieved by angiodynamics include, without limitation, the scale and scope of the covid-19 global pandemic, the ability of angiodynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of angiodynamics' technology or assertions that angiodynamics' technology infringes the technology of third parties, the ability of angiodynamics to effectively compete against competitors that have substantially greater resources, future actions by the fda or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of angiodynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of angiodynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in angiodynamics' sec filings, including but not limited to its annual report on form 10-k for the year ended may 31, 2022. angiodynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason. in the united states, the nanoknife system has received a 510(k) clearance by the food and drug administration for use in the surgical ablation of soft tissue and is similarly approved for commercialization in canada, the european union and australia. the nanoknife system has not been cleared for the treatment or therapy of a specific disease or condition. angiodynamics, inc. and subsidiaries consolidated income statements (in thousands, except per share data) three months ended aug 31, 2022 aug 31, 2021 (unaudited) net sales $ 81,537 $ 76,971 cost of sales (exclusive of intangible amortization) 39,232 36,832 gross profit 42,305 40,139 % of net sales 51.9 % 52.1 % operating expenses research and development 8,333 7,394 sales and marketing 26,543 24,446 general and administrative 10,101 8,943 amortization of intangibles 4,837 4,821 change in fair value of contingent consideration 211 195 acquisition, restructuring and other items, net 5,581 2,440 total operating expenses 55,606 48,239 operating loss (13,301 ) (8,100 ) interest expense, net (381 ) (156 ) other expense, net (175 ) (352 ) total other expense, net (556 ) (508 ) loss before income tax benefit (13,857 ) (8,608 ) income tax benefit (853 ) (1,636 ) net loss $ (13,004 ) $ (6,972 ) loss per share basic $ (0.33 ) $ (0.18 ) diluted $ (0.33 ) $ (0.18 ) weighted average shares outstanding basic 39,302 38,734 diluted 39,302 38,734 angiodynamics, inc. and subsidiaries gaap to non-gaap reconciliation (in thousands, except per share data) reconciliation of net loss to non-gaap adjusted net loss: three months ended aug 31, 2022 aug 31, 2021 (unaudited) net loss $ (13,004 ) $ (6,972 ) amortization of intangibles 4,837 4,821 change in fair value of contingent consideration 211 195 acquisition, restructuring and other items, net (1) 5,581 2,440 tax effect of non-gaap items (2) (111 ) (1,371 ) adjusted net loss $ (2,486 ) $ (887 ) reconciliation of diluted loss per share to non-gaap adjusted diluted loss per share: three months ended aug 31, 2022 aug 31, 2021 (unaudited) diluted loss per share $ (0.33 ) $ (0.18 ) amortization of intangibles 0.12 0.12 change in fair value of contingent consideration 0.01 0.01 acquisition, restructuring and other items, net (1) 0.14 0.06 tax effect of non-gaap items (2) — (0.03 ) adjusted diluted loss per share $ (0.06 ) $ (0.02 ) adjusted diluted sharecount (3) 39,302 38,734 (1) includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. (2) adjustment to reflect the income tax provision on a non-gaap basis has been calculated assuming no valuation allowance on the company's u.s. deferred tax assets and an effective tax rate of 23% for the periods ended august 31, 2022 and 2021. (3) diluted shares may differ for non-gaap measures as compared to gaap due to a gaap loss. angiodynamics, inc. and subsidiaries gaap to non-gaap reconciliation (continued) (in thousands, except per share data) reconciliation of net loss to adjusted ebitda: three months ended aug 31, 2022 aug 31, 2021 (unaudited) net loss $ (13,004 ) $ (6,972 ) income tax benefit (853 ) (1,636 ) interest expense, net 381 156 depreciation and amortization 7,621 6,958 change in fair value of contingent consideration 211 195 stock based compensation 3,024 2,429 acquisition, restructuring and other items, net (1) 5,581 2,440 adjusted ebitda $ 2,961 $ 3,570 per diluted share: adjusted ebitda $ 0.08 $ 0.09 (1) includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items. angiodynamics, inc. and subsidiaries net sales by product category and by geography (in thousands) three months ended aug 31, 2022 aug 31, 2021 % growth currency impact constant currency growth (unaudited) net sales med tech $ 22,817 $ 17,607 29.6 % med device 58,720 59,364 (1.1 )% $ 81,537 $ 76,971 5.9 % 0.6 % 6.5 % net sales by geography united states $ 69,023 $ 64,464 7.1 % international 12,514 12,507 0.1 % 3.7 % 3.8 % $ 81,537 $ 76,971 5.9 % 0.6 % 6.5 % gross profit by product category (in thousands) three months ended aug 31, 2022 aug 31, 2021 % change (unaudited) med tech $ 14,429 $ 11,517 25.3 % gross profit % of sales 63.2 % 65.4 % med device $ 27,876 $ 28,622 (2.6 ) % gross profit % of sales 47.5 % 48.2 % total $ 42,305 $ 40,139 5.4 % gross profit % of sales 51.9 % 52.1 % angiodynamics, inc. and subsidiaries consolidated balance sheets (in thousands) aug 31, 2022 may 31, 2022 (unaudited) (audited) assets current assets: cash and cash equivalents $ 24,564 $ 28,825 accounts receivable, net 53,586 52,304 inventories 57,609 51,392 prepaid expenses and other 15,612 10,824 total current assets 151,371 143,345 property, plant and equipment, net 46,189 45,005 other assets 11,078 10,963 intangible assets, net 147,976 152,380 goodwill 201,038 201,058 total assets $ 557,652 $ 552,751 liabilities and stockholders' equity current liabilities: accounts payable $ 29,258 $ 28,047 accrued liabilities 25,558 34,842 current portion of contingent consideration 8,892 8,783 other current liabilities 2,682 2,652 total current liabilities 66,390 74,324 long-term debt 49,798 25,000 deferred income taxes 15,115 16,037 contingent consideration 8,266 8,165 other long-term liabilities 4,042 4,736 total liabilities 143,611 128,262 stockholders' equity 414,041 424,489 total liabilities and stockholders' equity $ 557,652 $ 552,751 angiodynamics, inc. and subsidiaries consolidated statements of cash flows (in thousands) three months ended aug 31, 2022 aug 31, 2021 (unaudited) cash flows from operating activities: net loss $ (13,004 ) $ (6,972 ) adjustments to reconcile net loss to net cash used in operating activities: depreciation and amortization 7,660 6,997 non-cash lease expense 621 602 stock based compensation 3,024 2,429 change in fair value of contingent consideration 211 195 deferred income taxes (907 ) (1,690 ) change in accounts receivable allowances 45 (44 ) fixed and intangible asset impairments and disposals 87 30 other (96 ) (46 ) changes in operating assets and liabilities: accounts receivable (1,425 ) (36 ) inventories (6,238 ) (670 ) prepaid expenses and other (5,733 ) (3,354 ) accounts payable, accrued and other liabilities (8,990 ) (6,345 ) net cash used in operating activities (24,745 ) (8,904 ) cash flows from investing activities: additions to property, plant and equipment (809 ) (1,021 ) additions to placement and evaluation units (2,227 ) (4,471 ) acquisition of intangibles (540 ) — cash paid in acquisition — (3,600 ) net cash used in investing activities (3,576 ) (9,092 ) cash flows from financing activities: proceeds from borrowings on long-term debt 70,000 5,000 repayment of long-term debt (45,000 ) — deferred financing costs on long-term debt (706 ) — proceeds from exercise of stock options and employee stock purchase plan 82 446 net cash provided by financing activities 24,376 5,446 effect of exchange rate changes on cash and cash equivalents (316 ) (139 ) decrease in cash and cash equivalents (4,261 ) (12,689 ) cash and cash equivalents at beginning of period 28,825 48,161 cash and cash equivalents at end of period $ 24,564 $ 35,472
